Background
==========

Pancreaticoduodenectomy (PD) is associated with high postoperative morbidity. Despite improvement in surgical techniques, instruments, and perioperative management, postoperative pancreatic fistula (POPF) still remains the major complication and a challenging event in patients undergoing PD \[[@b1-medscimonit-24-5719]\]. POPF often leads to increased postoperative morbidity, prolonged hospital stays, increased medical costs, and sometimes to life-threatening complications such as massive abdominal hemorrhages. Despite significant efforts in preventing this problem, the rate of POPF remains essentially unchanged \[[@b2-medscimonit-24-5719],[@b3-medscimonit-24-5719]\].

A uniform standard and definition for perioperative complications is crucial for surgical research. The International Study Group for Pancreatic Fistula (ISGPF) first proposed a standardized definition for POPF in 2005 \[[@b4-medscimonit-24-5719]\]. In the past decade, some risk factors for POPF has been identified according to the 2005 grading system, such as sex, body mass index, status of the pancreatic parenchyma, diameter of the main pancreatic duct, kind of diseases, and bile juice infection \[[@b5-medscimonit-24-5719],[@b6-medscimonit-24-5719]\]. However, despite the widespread use of the 2005 classification in the majority of published studies, several limitations still exist. For example, the definition of grade A POPF was considered too broad and lacks clinical consequences. The reported rates of grade A POPFs in the published literatures range from almost 0% to 50%, suggesting its rate was either over- or under-estimated in past researches \[[@b7-medscimonit-24-5719],[@b8-medscimonit-24-5719]\]. Additionally, there is a lack of clear classification of POPF as grade B or C when requiring an "invasive procedure" due to the presence of a "grey area" in the 2005 classification regarding whether the presence of some clinical procedures should move the grade of POPF from grade B to grade C \[[@b9-medscimonit-24-5719],[@b10-medscimonit-24-5719]\].

In order to clarify and further refine the classification, the ISGPF revised the 2005 POPF definition and published the 2016 classification and grading of POPF \[[@b11-medscimonit-24-5719]\]. A new concept of "biochemical leak (BF)" replaced the former grade A POPF. The grade A POPF is no longer considered a true pancreatic fistula because it has no clinical importance. In addition to a more accurate distinction between the grades B and C, the new 2016 classification stresses that a true POPF should have an impact on the clinical invention and outcome of the patient. To be defined strictly as a POPF, this condition needs to be clinically relevant. A clinically relevant postoperative pancreatic fistula (CR-POPF) is now redefined as a drain output of any measurable volume of fluid with an amylase level \>3 times the upper limit of institutional normal serum amylase activity, associated with a clinically relevant development/condition related directly to the postoperative pancreatic fistula \[[@b11-medscimonit-24-5719]\].

Recent large-scale studies clarified the reliability of the new definition and revealed it could better stratify distinct conditions that differ in clinical and economic outcomes \[[@b12-medscimonit-24-5719],[@b13-medscimonit-24-5719]\]. However, there have been no reports on the risk factors related to CR-POPF based on the new definition. The aim of the present study was to identify perioperative risk factors of CR-POPF in a retrospective cohort of 225 patients undergoing pancreaticoduodenectomy in a single center.

Material and Methods
====================

Patients and data
-----------------

We retrospectively examined our prospectively maintained database of 361 consecutive patients who underwent PD at Guangdong General Hospital between January 01, 2009 and December 31, 2017. The 225 consecutive patients who underwent PD between January 01, 2009 and November 31, 2015 were assigned to the study group and the other 136 consecutive patients who underwent PD between December 01, 2015 and December 31, 2017 were assigned to the validation group.

The primary outcome, CR-POPF, was defined in accordance with the updated 2016 ISGPF consensus guidelines. Postoperative outcomes were analyzed with regards to POPF occurrence and its management, organ failure, mortality through 90 days after the operation, the occurrence of major surgical complications \[Clavien-Dindo (CD) \>3\], postoperative mortality, length of hospital stay, and overall hospitalization costs. Demographic and preoperative clinical data were collected and were used to construct a predictive scoring model to predict the risk of CR-POPF after PD. The data obtained from the validation group were used for the internal validation of the predictive scoring model. The study was approved by the Medical Ethics Review Committee of Guangdong General Hospital.

Surgical procedures for PD
--------------------------

There were 7 surgeons who performed PD during this period, and surgical technique was largely performed by standard procedures. Generally, the operation was performed by using either classic PD or pylorus-preserving PD (PPPD) techniques. End-to-side, mucosa-mucosa anastomosis was the first choice for pancreaticojejunostomy. The pancreatic duct stent was not routinely used. In cases of very narrow pancreatic duct, or if it was impossible to expose the pancreas, an end-to-end pancreaticojejunostomy was performed. Usually, 3 abdominal drainage tubes were applied. One drainage tube was placed near the site of bile duct anastomosis, and the other 2 tubes were placed near the site of the pancreatic anastomosis. The techniques used primarily included both the classic PD and PPPD. During 2009--2015, the pancreatic resection volume remained stable. During the study period, there was a transition from classic Whipple operations to PPPD.

Statistical analysis
--------------------

Statistical analyses were performed using SPSS Statistics for Windows version 17.0 (IBM Corp., Armonk, NY) and R for Windows version 3.4.1. Categorical variables were analyzed using the Chi-squared test and continuous variables were analyzed using the *t* test. Multivariate analysis was done for all variables with P values of less than 0.1 by univariate analysis with a logistic regression analysis. Receiver operating characteristic (ROC) curves and the corresponding area under the curve (AUC) were used to evaluate how the prediction model performed on the test data. A P value of less than 0.05 was considered statistically significant.

Results
=======

Patients' characteristics
-------------------------

[Table 1](#t1-medscimonit-24-5719){ref-type="table"} summarizes the demographic character of all 361 patients. The mean age of included patients was 58.2±12.2 years, 59.8% were male, and 40.2% were female. One hundred ninety-one (85.3%) patients underwent pancreaticoduodenectomy for malignant diseases and 34 (14.7%) patients underwent pancreaticoduodenectomy for benign diseases. Serious (grades III--V) complications occurred in 101 patients (28.0%). Clinically relevant pancreatic fistulas (CR-POPF) were documented in 40 (POPF grade B occurred in 30 and POPF grade C occurred in 10) patients in the study group and in 21 (POPF grade B occurred in 16 and POPF grade C occurred in 5) patients in the validation group.

Univariate and multivariate analyses of clinical variables in relation to CR-POPF after pancreaticoduodenectomy
---------------------------------------------------------------------------------------------------------------

[Table 2](#t2-medscimonit-24-5719){ref-type="table"} lists the relationship between perioperative clinical variables and CR-POPF after pancreaticoduodenectomy based on the data of the study group. In univariate analysis, the main pancreatic duct diameter (MPD) (P=0.008), soft pancreas (P=0.019), intraoperative blood loss (P=0.011), extended lymphadenectomy (P=0.022), and serum albumin of the first postoperative day (postoperative day 1 albumin) (P=0.001) were significantly higher in patients with CR-POPF. The following factors were entered into the multivariate analysis since the P values were found to be less than 0.1 in univariate analysis: the MPD, pancreas thickness, pancreas texture, intraoperative blood loss, extended lymphadenectomy, and postoperative day 1 albumin. As shown in [Table 3](#t3-medscimonit-24-5719){ref-type="table"}, multivariate logistic regression analysis identified pancreas texture (soft versus hard: OR 2.09, 95%CI 1.10--3.98, P=0.025), MPD (≤2.5 mm versus \>2.5 mm, OR 2.72, 95%CI 1.23--5.99, P=0.013), extended lymphadenectomy (Yes versus No, OR 1.57, 95%CI 1.13--2.18, P=0.007), and postoperative day 1 serum albumin (≤25 g/L versus \>30g/L, OR 5.12, 95%CI 1.82--14.41, P=0.002; 25--30 g/L versus \>30 g/L, OR 1.43, 95%CI 1.02--2.00, P=0.037) were independent risk factors for CR-COPF.

The logistic regression model provided the estimated probability of CR-POPF after pancreaticoduodenectomy. This probability was equal to y=1/(1+e^−Z^), where e is the base value of natural logarithms (a mathematical constant, ≈2.718281828459), and Z=−5.367+0.992×pancreas texture (0, hard pancreas; 1, soft pancreas) +1.421×MPD (0, \>2.5 mm; 1, ≤2.5 mm) +0.587×extended lymphadenectomy (0,No; 1, Yes) +(3.87×albumin (0, \>30 g/L; 1, ≤25 g/L) or 0.419×albumin (0, \>30 g/L; 1, 25--30 g/L)).

We developed a score using variables based on the regression coefficient of the logistic regression model ([Table 4](#t4-medscimonit-24-5719){ref-type="table"}). The equation for the scoring system was calculated on the assumption that a patient receives 1 point for a soft pancreas, 1.5 points for MPD ≤2.5 mm, 0.5 points for extended lymphadenectomy, 3 points for postoperative day 1 albumin ≤25 g/L, and 0.5 points for albumin 25--30 g/L. The predictive value of this scoring system was also assessed in a validation group. The comparison between characteristics of patients are shown in [Table 5](#t5-medscimonit-24-5719){ref-type="table"}. As shown in [Figure 1](#f1-medscimonit-24-5719){ref-type="fig"}, the ROC curves based on the above scoring system show that the area under the curve (AUC) was 0.813 (95%CI: 0.737--0.889) in the study group (AUC1) and 0.806 (95%CI: 0.735--0.878) in the validation group (AUC2), respectively. The high AUC value in the validation group suggested that this scoring system was highly predictive of CR-POPF. Based on the sensitivities and specificities of every score, we concluded that a score ≥4.5 could be used as a threshold to identify patients with high risk of developing CR-POPF.

Discussion
==========

Postoperative PF (POPF) after pancreatic surgery remains a challenging event in high-volume pancreatic centers. Currently, a variety of risk factors related to POPF have been identified, such as sex, pancreatic texture, body mass index, and MPD. The 2016 new definition and grading of POPF by ISGPF highlighted the concept that the fistula must be a clinically relevant condition. Prediction of CR-POPF remains controversial, and many studies focused on preoperative factors but only few studies take into account postoperative factors. In the present study, we searched both preoperative and postoperative risk factors for the development of CR-POPF, and found that soft pancreatic texture, MPD, extended lymphadenectomy, and postoperative serum albumin were independent risk factors related to CR-POPF. These findings characterized a high-risk patient group for CR-POPF after pancreaticoduodenectomy.

Soft pancreatic texture and low serum albumin have been accepted as significant risk factors for POPF. In this study, both soft pancreas and postoperative serum albumin were identified as independent factors related to CR-POPF. Patients with a soft pancreas usually have a smaller pancreatic duct diameter and a larger parenchymal thickness than those with a hard pancreas. Histologic evaluation of soft pancreas showed a larger area of the cut surface, a smaller fibrosis ratio, and a larger lobular ratio.14 Decreased fibrosis in pancreatic tissue is associated with increased exocrine activity \[[@b15-medscimonit-24-5719],[@b16-medscimonit-24-5719]\] Additionally, a fatty pancreas might be more friable and is more easily disrupted during anastomosis than is a hard pancreas \[[@b17-medscimonit-24-5719]\]. Relles et al. reported that hypoalbuminemia on postoperative day 1 was an independent predictive marker for complications after pancreaticoduodenectomy, which was consistent with our findings. Serum albumin is associated with nutritional status, and hypoalbuminemia is often associated with protein turnover and poor tissue healing, which attributes to anastomotic leakage \[[@b18-medscimonit-24-5719]--[@b20-medscimonit-24-5719]\].

Extended lymphadenectomy has not been investigated previously as a risk factor for PF after PD. In an earlier study, Yeo et al. \[[@b21-medscimonit-24-5719]\] reported that periampullary adenocarcinoma patients undergoing radical pancreaticoduodenectomy (with the addition of a distal gastrectomy and extended retroperitoneal lymphadenectomy to a standard pancreaticoduodenectomy) had a significantly higher incidence of pancreatic fistula when comparing the standard pancreaticoduodenectomy (13% *vs.* 6%; P=0.05). A recent study reported that extended lymphadenectomy was an independent risk factor for clinical pancreatic fistula after distal pancreatectomy \[[@b22-medscimonit-24-5719]\]. On the other hand, the high morbidity rate also was reported in patients with pancreatic body cancer who underwent extended lymphadenectomy.23 The higher rate of pancreatic fistula in the radical group also is not clearly explainable.

Several scoring systems have been reported before \[[@b24-medscimonit-24-5719]--[@b28-medscimonit-24-5719]\]. A comparison between the present scoring system and these existing scoring systems in term of CR-POPF based on the validation group is summarized in [Table 6](#t6-medscimonit-24-5719){ref-type="table"}. The systems by Yamamoto \[[@b28-medscimonit-24-5719]\], Wellner \[[@b25-medscimonit-24-5719]\], and Roberts \[[@b27-medscimonit-24-5719]\] use easily measurable radiological and demographic variables and may be constructed preoperatively. Preoperative risk stratification has certain advantages, including the opportunity to individualize patient consent, to facilitate training opportunities in low-risk patients, and to select optimal patients for clinical trials. However, due to the exclusion of intraoperative and postoperative factors, the predictive value of preoperative scoring systems might be compromised. Some studies included postoperative pathological factors in their scoring system. For example, Gaujoux et al. \[[@b24-medscimonit-24-5719]\] proposed a predictive scoring system using BMI, pancreatic fibrosis, and the presence of fatty pancreas. Although their scoring system is quite useful for estimating POPF, it requires pathological examination; therefore, the final score can be delayed until several days after the operation. To address the risk of POPF accurately and quickly, we included preoperative and intraoperative factors, as well as factors on the first postoperative day. Additionally, unlike most other scoring systems, the present study just selected patients with "clinically relevant" pancreatic fistula (ISGPF types B and C), making our scoring system more clinically significant.

Additional scores have been proposed to predict POPF in patients undergoing a general pancreatic resection. Belyaev et al. \[[@b29-medscimonit-24-5719]\] proposed a scoring system based on histomorphological features of the pancreatic remnant, and Nahm et al30 suggested that acinar cell density in the pancreatic resection margin was significantly associated with POFP for all pancreatic resections. Because the results of histomorphological features and acinar cell density depend on the pathological examination, the final score could be delayed until several days postoperatively, but these pathological parameters showed good predictive value in past studies; they warrant rapid pathological examinations if their predictive value can be firmly established by further studies. Another study, by Nahm et al. \[[@b31-medscimonit-24-5719]\], reported that intraoperative amylase concentration was significantly correlated with POPF in patients who underwent distal pancreatectomy. Both intraoperative amylase concentration and acinar cell density are unconventional risk factors that were not evaluated in our center before. Further studies are needed to confirm their value in predicting CR-POPF alone or as part of a scoring system.

In the present study, the validation group had a significantly increased rate of PPPD procedure and proportion of duct-to-mucosa anastomosis. PPPD is now the first choice in our center, and we use duct-to-mucosa anastomosis as often as we can. The albumin level in the validation group was significantly higher than in the study group. This difference can be explained by the preoperative nutritional assessment and support. Since more than 2 years ago, we started to routinely assess nutritional status by using NRS2002 in patients who were planned to undergo pancreaticoduodenectomy, and the nutritional support treatment was performed in patients with NRS2002 score ≥3. Despite the differences in baseline characteristics of patients in these 2 groups, the AUC in the validation group was 0.806, suggesting the extrapolation of our scoring system is high.

Conclusions
===========

Despite these limitations, this study has developed a novel predictive scoring system for CR-POPF after PD, with good extrapolation ability. This scoring system may help surgeons to identify and control CR-POPF earlier, in order to improve the management of POPF and prevent more severe complications.
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![Two receiver operating characteristic (ROC) curves for the estimated probability of CR-POPF calculated based on the scoring system. The area under the curve for the study group (AUC1) was 0.813 (95%CI: 0.737--0.889) and the area under the curve for the validating group (AUC2) was 0.806 (95%CI: 0.735--0.878).](medscimonit-24-5719-g001){#f1-medscimonit-24-5719}

###### 

Patient characteristics for 361 patients underwent pancreaticoduodenectomy.

                                      N           \%
  ----------------------------------- ----------- ------
  Age (years, mean ± sd.)             58.2±12.2   
  Gender                                          
   Male                               216         59.8
   Female                             145         40.2
  Disease                                         
   Pancreatic ductal adenocarcinoma   92          25.5
   Bile duct cancer                   22          6.1
   Ampullary cancer                   102         28.3
   Duodenal neoplasm                  62          17.2
   IPMN                               5           1.4
   PNET                               23          6.4
   Pancreatic serous cystadenoma      6           1.7
   Papillary mucinous cystadenoma     3           0.8
   Chronic pancreatitis               16          4.4
   Others                             30          8.3
  Pathology                                       
   Malignant                          308         85.3
   Benign                             53          14.7

sd -- standard deviation; IPMN -- intraductal papillary mucinous neoplasm; PNET -- pancreatic neuroendocrine tumors.

###### 

Univariate analyses of factors associated with CR-POPF after pancreaticoduodenectomy in the study group.

  -----------------------------------------------------------------------------------
  Factor                               Patients without\   Patients with\   P value
                                       CR-POPF (n=185)     CR-POPF (n=40)   
  ------------------------------------ ------------------- ---------------- ---------
  Age (years, mean ±sd.)               57.7±12.5           60.2±9.8         0.245

  Gender                                                                    0.801

   Male                                107                 24               

   Female                              78                  16               

  History of diabetes                                                       0.376

   Yes                                 15                  5                

   No                                  170                 35               

  Jaundice                                                                  0.158

   Yes                                 100                 30               

   No                                  85                  10               

  ASA-PS                                                                    

   1                                   57                  9                

   2 or 3                              128                 31               

  Disease                                                                   0.341

   Malignant                           159                 32               

   Benign                              26                  8                

  Relation to portal vein on CT                                             0.271

   Involved portal vein                17                  6                

   Away from portal vein               168                 34               

  MPD diameter (mm, mean ±sd.)         3.65±2.36           2.70±1.60        0.008

  Pancreas thickness (mm, mean ±sd.)   13.10±1.36          13.92±1.71       0.081

  Pancreas texture                                                          0.019

   Soft                                65                  22               

   Hard                                120                 18               

  Blood loss (ml, mean ±sd.)           355.83±390.73       589.66±520.54    0.011

  Operation time (min, mean ±sd.)      426.21±106.82       439.74±99.57     0.261

  Procedure                                                                 0.837

   PD                                  21                  5                

   PPPD                                164                 35               

  Extended lymphadenectomy                                                  0.022

   Yes                                 38                  15               

   No                                  147                 25               

  Pncreaticojejunostomy                                                     0.360

   Duct-to-mucosa                      121                 22               

   Dunking method                      57                  15               

   Others                              7                   3                

  Pancreatic duct stent                                                     0.345

   Internal stent                      64                  17               

   None                                121                 23               

  Preoperative CA19-9                  180.56±289.46       192.91±269.35    0.805

  Preoperative CA125                   20.52±19.86         17.06±10.24      0.310

  Preoperative CEA                     4.92±11.36          5.69±10.20       0.691

  Albumin                                                                   

   Preoperative                        32.9±6.1            32.7±4.8         0.898

   Postoperative Day 1                 25.9±4.96           23.8±4.04        0.001

  Total bilirubin                                                           

   Preoperative                        147.69±141.36       169.06±143.43    0.389

   Postoperative Day 1                 124.24±126.96       155.92±105.26    0.143

  Direct bilirubin                                                          

   Preoperative                        83.01±79.77         96.24±78.33      0.347

   Postoperative Day 1                 68.36±73.56         82.82±62.15      0.250

  Hemoglobin                                                                

   Preoperative                        119.34±19.04        120.18±18.66     0.799

   Postoperative Day 1                 114.66±75.98        105.69±14.02     0.460

  White blood cell                                                          

   Preoperative                        7.16±2.59           6.99±2.08        0.696

   Postoperative Day 1                 13.26±4.40          13.80±4.91       0.498

  Platelet                                                                  

   Preoperative                        278.62±93.00        297.58±99.73     0.251

   Postoperative Day 1                 251.36±93.69        262.91±101.69    0.488

  Blood glucose                                                             

   Preoperative                        6.16±2.42           5.92±1.54        0.545

   Postoperative Day 1                 10.97±10.05         11.09±4.65       0.941

  PT                                                                        

   Preoperative                        14.22±1.51          12.81±1.81       0.447

   Postoperative Day 1                 14.68±1.32          13.27±1.92       
  -----------------------------------------------------------------------------------

sd -- standard deviation; BMI -- body mass index; PT -- prothrombin time; Na -- natrium; K -- kalium; Mg -- magnesium; Ca -- calcium; MPD -- main pancreatic duct diameter; ASA-PS -- American Society of Anesthesiologists-physical status.

###### 

Results of multivariate analysis of factors predicting CR-POPF.

  Variable                        Category                     OR     95%CI         P value
  ------------------------------- ---------------------------- ------ ------------- ---------
  Pancreas texture                Soft versus Hard             2.09   1.10--3.98    0.025
  MPD                             ≤2.5 mm versus \>2.5 mm      2.72   1.23--5.99    0.013
  Extended lymphadenectomy        Yes versus No                1.57   1.13--2.18    0.007
  Postoperative day 1 serum ALB   ≤25 g/L versus \>30 g/L      5.12   1.82--14.41   0.002
  Postoperative day 1 serum ALB   25--30 g/L versus \>30 g/L   1.43   1.02--2.00    0.037

MPD -- main pancreatic duct diameter; ALB -- albumin; Mg -- magnesium.

###### 

Score of each variable in the predictive scoring system for pancreatic fistula.

  Variables                     Points
  ----------------------------- --------
  Pancreas texture              
   Soft pancreas                1
   Hard pancreas                0
  MPD                           
   ≤2.5 mm                      1.5
   \>2.5 mm                     0
  Extended lymphadenectomy      
   Yes                          0.5
   No                           0
  Postoperative day 1 albumin   
   ≤25 g/L                      3
   25--30 g/L                   0.5
   \>30 g/L                     0

###### 

Comparison of the characters between the study group and the validation group.

  Factor                               Patients without (n=225)   Patients with (n=136)   P value
  ------------------------------------ -------------------------- ----------------------- ---------
  Age (years, mean ±sd.)               58.1±12.1                  58.3±12.5               0.986
  Gender                                                                                  0.422
   Male                                131                        85                      
   Female                              94                         51                      
  History of diabetes                                                                     0.273
   Yes                                 20                         17                      
   No                                  205                        119                     
  Jaundice                                                                                0.447
   Yes                                 130                        73                      
   No                                  95                         63                      
  ASA-PS                                                                                  0.987
   1                                   66                         40                      
   2 or 3                              159                        96                      
  CR-POPF                                                                                 0.918
   Grade B                             30                         16                      
   Grade C                             10                         5                       
  Disease                                                                                 0.767
   Malignant                           191                        117                     
   Benign                              34                         19                      
  Relation to portal vein on CT                                                           0.282
   Involved portal vein                23                         19                      
   Away from portal vein               202                        117                     
  MPD diameter (mm, mean ±sd.)         3.48±2.27                  3.50±2.63               0.906
  Pancreas thickness (mm, mean ±sd.)   13.25±1.46                 13.21±1.81              0.879
  Pancreas texture                                                                        0.153
   Soft                                87                         63                      
   Hard                                138                        73                      
  Blood loss (ml, mean ±sd.)           397.40±424.98              367.25±390.77           0.671
  Operation time (min, mean ±sd.)      428.62±105.48              409.46±112.58           0.779
  Procedure                                                                               0.004
   PD                                  26                         5                       
   PPPD                                199                        131                     
  Extended lymphadenectomy                                                                0.868
   Yes                                 53                         31                      
   No                                  172                        105                     
  Pncreaticojejunostomy                                                                   0.001
  Duct-to-mucosa                       143                        131                     
   Dunking method                      72                         0                       
   Others                              10                         5                       
  Pancreatic duct stent                                                                   0.163
   Internal stent                      81                         59                      
   None                                144                        77                      
  Albumin                                                                                 
   Preoperative                        32.9±5.9                   35.2±5.1                0.023
   Postoperative Day 1                 25.5±4.9                   29.8±4.8                0.001
  Hemoglobin                                                                              
   Preoperative                        119.49±18.93               121.36±19.52            0.516
   Postoperative Day 1                 105.69±69.20               111.66±21.37            0.298
  White blood cell                                                                        
   Preoperative                        7.13±2.50                  7.06±2.73               0.812
   Postoperative Day 1                 13.36±4.49                 13.47±5.62              0.701
  Platelet                                                                                
   Preoperative                        281.99±94.28               287.71±96.43            0.834
   Postoperative Day 1                 253.41±95.03               249.61±97.29            0.912

###### 

Comparison between the present scoring system and existing scoring systems.

  Score system                                     Scoring factors    Population                                                             AUC[\*](#tfn5-medscimonit-24-5719){ref-type="table-fn"}
  ------------------------------------------------ ------------------ ---------------------------------------------------------------------- ---------------------------------------------------------
  The present study                                9, 10, 12, 13      Pancreatoduodenectomy                                                  0.806
  Gaujoux et al. \[[@b24-medscimonit-24-5719]\]    4, 14, 15          Pancreatoduodenectomy                                                  0.801
  Wellner et al. \[[@b25-medscimonit-24-5719]\]    1, 3, 5, 6, 7      Pancreatoduodenectomy                                                  0.656
  Callery et al. \[[@b26-medscimonit-24-5719]\]    7, 8, 9, 10        Pancreatoduodenectomy                                                  0.789
  Roberts et al. \[[@b27-medscimonit-24-5719]\]    4, 10              Pancreatoduodenectomy                                                  0.702
  Yamamoto et al. \[[@b28-medscimonit-24-5719]\]   2, 7, 10, 11, 16   Pancreatoduodenectomy                                                  0.734
  Belyaev et al. \[[@b29-medscimonit-24-5719]\]    10, 19             Pancreatoduodenectomy, distal pancreatectomy                           NA
  Nahm et al. \[[@b30-medscimonit-24-5719]\]       17                 Pancreatoduodenectomy, distal pancreatectomy, central pancreatectomy   NA
  Nahm et al. \[[@b31-medscimonit-24-5719]\]       18                 Distal pancreatectomy                                                  NA

1 -- age; 2 -- gender; 3 -- smoking history; 4 -- BMI; 5 -- weight loss; 6 --, pancreatitis history; 7 -- preoperative diagnosis other than pancreatic cancer or chronic pancreatitis; 8 -- blood loss; 9 -- pancreatic texture; 10 -- pancreatic duct diameter; 11 -- relation of portal vein to tumor; 12 -- extended lymphadenectomy; 13 -- serum albumin of postoperative day 1; 14 -- pancreatic fibrosis; 15 -- presence of fatty pancreas, 16 -- intra-abdominal fat thickness; 17 -- acinar cell density at the pancreatic resection margin; 18 -- intra-operative amylase concentration; 19 -- histomorphological features including periductal fibrosis, interlobular fibrosis, intralobular fibrosis, interlobular fat, intralobular fat, signs of chronic pancreatitis, signs of acute pancreatitis, tissue edema. AUC -- area under the curve; NA -- result was not available due to lack of data.

AUC was obtained by the receiver operating characteristic (ROC) curve analysis in the validation group.
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